PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING MIGAINES
The present invention provides a method for treating or preventing one or more types of migraines by administering a monoamine oxidase inhibitor, preferably isocarboxazid, in a rapid-release formulation. The present invention also provides a pharmaceutical composition suitable for treating or preventing migraines and having at least one monoamine oxidase inhibitor.
1 . A pharmaceutical composition comprising at least an amount of a monoamine oxidase inhibitor effective for the relief of migraine in a human subject, wherein the composition releases an effective amount of monoamine oxidase inhibitor into the bloodstream of the subject within about 5 minutes of administration, with the proviso that the monoamine oxidase inhibitor is not selegiline.
2 . The composition according to claim 1 , wherein the composition releases an effective amount of monoamine oxidase inhibitor into the blood stream of the subject within about 2 minutes of administration.
3 . The composition according to claim 2 , wherein the composition releases and effective amount of monoamine oxidase inhibitor into the blood stream of the subject within about 1 minute of administration.
4 . A composition according to claim 1 , wherein the composition is adapted for intranasal administration.
5 . A composition according to claim 1 , wherein the composition is adapted for buccal or sublingual administration.
6 . A composition according to claim 1 , wherein the composition is adapted for pulmonary administration.
7 . A composition according to claim 5 , wherein the composition further comprises a sustained-release component, said sustained-release component comprising a monoamine oxidase inhibitor and adapted for oral administration.
8 . The composition according to claim 7 , wherein said sustained-release component releases monoamine oxidase inhibitor at a rate that maintains a blood level of monoamine oxidase inhibitor effective to treat or prevent migraine for at least 8 hours.
9 . The composition according to claim 8 , wherein said sustained-release component releases monoamine oxidase inhibitor at a rate that maintains a blood level of monoamine oxidase inhibitor effective to treat or prevent migraine for at least 12 hours.
10 . The composition according to claim 9 , wherein said sustained-release component releases monoamine oxidase inhibitor at a rate that maintains a blood level of monoamine oxidase inhibitor effective to treat or prevent migraine for at least 24 hours.
11 . A pharmaceutical composition comprising at least an amount of isocarboxazid effective for the relief of migraine in a human subject, wherein the composition releases an effective amount of isocarboxazid into the bloodstream of the subject within about 5 minutes of administration.
12 . The composition according to claim 11 , wherein the composition releases an effective amount of isocarboxazid into the bloodstream of the subject within about 2 minutes of administration.
13 . The composition according to claim 12 , wherein the composition releases an effective amount of isocarboxazid into the bloodstream of the subject within about 1 minute of administration.
14 . A composition according to claim 11 , wherein the composition is adapted for intranasal administration.
15 . A composition according to claim 11 , wherein the composition is adapted for buccal or sublingual administration.
16 . A composition according to claim 11 , wherein the composition is adapted for pulmonary administration.
17 . A composition according to claim 15 , wherein the composition further comprises a sustained-release component, said sustained-release component comprising isocarboxazxid and adapted for oral administration.
18 . The composition according to claim 17 , wherein said sustained-release component releases isocarboxazid at a rate that maintains a blood level of isocarboxazid effective to treat or prevent migraine for at least 8 hours.
19 . The composition according to claim 18 , wherein the sustained-release component releases isocarboxazid at a rate that maintains a blood level of isocarboxazid effective to treat or prevent migraine for at least 12 hours.
20 . The composition according to claim 19 , wherein the sustained-release component releases isocarboxazid at a rate that maintains a blood level of isocarboxazid effective to treat or prevent migraine for at least 24 hours.
21 . A method for the prevention or relief of migraine in a human subject, comprising administration to the subject of a composition according to claim 1 .
22 . A method for the prevention or relief of migraine in a human subject, comprising administration to the subject of a composition according to claim 4 .
23 . A method for the prevention or relief of migraine in a human subject, comprising administration to the subject of a composition according to claim 5 .
24 . A method for the prevention or relief of migraine in a human subject, comprising administration to the subject of a composition according to claim 6 .
25 . A method for the prevention or relief of migraine in a human subject, comprising administration to the subject of a composition according to claim 7 .
26 . A method for the prevention or relief of migraine in a human subject, comprising administration to the subject, of a composition according to claim 11 .
27 . A method for the prevention or relief of migraine in a human subject, comprising administration to the subject of a composition according to claim 14 .
28 . A method for the prevention or relief of migraine in a human subject, comprising administration to the subject of a composition according to claim 15 .
29 . A method for the prevention or relief of migraine in a human subject, comprising administration to the subject of a composition according to claim 16 .
30 . A method for the prevention or relief of migraine in a human subject, comprising administration to the subject of a composition according to claim 17 .
31 . A method for the prevention or relief of migraine in a human subject, comprising administration to the subject of a composition comprising at least an amount of a monoamine oxidase inhibitor effective for the relief of migraine in a human subject, wherein the composition releases an effective amount of monoamine oxidase inhibitor into the bloodstream of the subject within about 5 minutes of administration.